Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bupropion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 10/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 8/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 5/20 | 1.00 |
| ▸ | CHRNG | P07510 | 5/20 | 1.00 |
| ▸ | CHRNB1 | P11230 | 5/20 | 1.00 |
| ▸ | CHRNB2 | P17787 | 5/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 5/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 5/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 5/20 | 1.00 |
| ▸ | CHRND | Q07001 | 5/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 4/20 | 1.00 |
| ▸ | ITGA5 | P08648 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.97 |
| ▸ | BLM | P54132 | 1/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bupropion SCHEMBL60314 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL30679332 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL12499296 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL29424575 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL29354885 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL300444 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL5608195 | 0.98 | SLC6A3 (0.97) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL636116 | 0.98 | SLC6A3 (0.97) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL4972526 | 0.98 | SLC6A3 (0.97) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL31748783 | 0.98 | SLC6A2 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 42098 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144782-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | AUSPEX PHARMACEUTICALS LLC (US) | 2026-05-28 | — | — | US | claimed |
| US-20260144765-A1 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | ANTECIP BIOVENTURES II LLC (US) | 2026-05-28 | — | — | US | claimed |
| US-20260144764-A1 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | ANTECIP BIOVENTURES II LLC (US) | 2026-05-28 | — | — | US | claimed |
| EP-4748444-A2 | COMPOSITIONS COMPRISING CYTISINE IN THE TREATMENT AND/OR PREVENTION OF ADDICTION IN SUBJECTS IN NEED THEREOF | Achieve Life Sciences, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122075465-A | Use of propionyl carnitine for improving obesity and insulin resistance | — | 2026-05-26 | — | — | CN | claimed |
| CN-122094687-A | Compounds and combinations thereof for the treatment of neurological and psychiatric disorders | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026107265-A1 | PHARMACEUTICAL DOSAGE FORMS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | ANTECIP BIOVENTURES II LLC (US) | 2026-05-21 | — | — | WO | claimed |
| CN-122031677-A | Leptin receptor agonist antibodies for the treatment of metabolic dysfunction or hypoleptinemia | 瑞泽恩制药公司 | 2026-05-15 | — | — | CN | claimed |
| US-20260130871-A1 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | ANTECIP BIOVENTURES II LLC (US) | 2026-05-14 | — | — | US | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| EP-0171227-B1 | USE OF PROPIOPHENONE COMPOUND | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-11-02 | — | — | EP | claimed |
| EP-0204954-A2 | Use of dopamine agonists for the manufacture of a medicament for the treatment of psychostimulant addiction | SANDOZ AG (CH) | 1986-12-17 | — | — | EP | claimed |
| US-4571395-A | Lorazepam and bupropion, compositions and methods | BURROUGHS WELLCOME CO. (US) | 1986-02-18 | — | — | US | claimed |
| EP-0171227-A1 | Use of propiophenone compound | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-02-12 | — | — | EP | claimed |
| EP-0038071-B1 | NEW UNLABELLED AND RADIOACTIVE LABELLED DERIVATIVES OF BUTYLAMINO PROPIOPHENONE, THEIR PREPARATION, IMMUNOGENS OBTAINED FROM THE UNLABELLED DERIVATIVES AND A PROCESS FOR IMMUNOGEN PREPARATION, ANTISERA RAISED USING THE IMMUNOGENS AND A METHOD FOR RAISING ANTISERA, A RADIOIMMUNOASSAY METHOD AND A TEST KIT FOR USE IN THE ASSAY METHOD | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-11-14 | — | — | EP | claimed |
| EP-0118036-A1 | Biologically active ketone derivative, preparation and use | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-09-12 | — | — | EP | claimed |
| US-4356165-A | Bupropion radioimmunoassay, and kit | BURROUGHS WELLCOME CO. (US) | 1982-10-26 | — | — | US | claimed |
| US-4347257-A | Prolactin suppression in mammals | BURROUGHS WELLCOME CO. (US) | 1982-08-31 | — | — | US | claimed |
| US-4347178-A | Compounds and methods of making | BURROUGHS WELLCOME CO. (US) | 1982-08-31 | — | — | US | claimed |
| EP-0038071-A2 | New unlabelled and radioactive labelled derivatives of butylamino propiophenone, their preparation, immunogens obtained from the unlabelled derivatives and a process for immunogen preparation, antisera raised using the immunogens and a method for raising antisera, a radioimmunoassay method and a test kit for use in the assay method | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-10-21 | — | — | EP | claimed |